Rs7997012
| Orientation | plus |
| is a | snp |
| is | mentioned by |
| dbSNP | rs7997012 |
| PheGenI | rs7997012 |
| nextbio | rs7997012 |
| hapmap | rs7997012 |
| 1000 genomes | rs7997012 |
| hgdp | rs7997012 |
| ensembl | rs7997012 |
| gopubmed | rs7997012 |
| geneview | rs7997012 |
| scholar | rs7997012 |
| rs7997012 | |
| pharmgkb | rs7997012 |
| gwascentral | rs7997012 |
| openSNP | rs7997012 |
| 23andMe | rs7997012 |
| 23andMe all | rs7997012 |
| SNP Nexus | |
| SNPshot | rs7997012 |
| SNPdbe | rs7997012 |
| MSV3d | rs7997012 |
| Gene | HTR2A |
| Chromosome | 13 |
| Orientation | plus |
| GMAF | 0.2738 |
| Position | 47411985 |
| Reference | GRCh37 37.1/131 |
| Max Magnitude | 0 |
| Geno | Mag | Summary |
|---|---|---|
| (A;A) | ~18% more likely to respond to citalopram | |
| (A;G) | 0 | normal risk |
| (G;G) | ~18% less likely to respond to citalopram |
| ? | (A;A) (A;G) (G;G) | 28 |
|---|---|---|
From this article [PMID 16642436]:
"HTR2A encodes the serotonin 2A receptor, which is downregulated by citalopram. Participants who were homozygous for the A allele had an 18% reduction in absolute risk of having no response to treatment, compared with those homozygous for the other allele."
- See also Anxiety Blog posting
[PMID 19095219] Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder
[PMID 19428704] Genetic association analysis of serotonin 2A receptor gene (HTR2A) with bipolar disorder and major depressive disorder in the Japanese population
[PMID 19590397] 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression
[PMID 19924111] Polymorphisms in GRIK4, HTR2A, and FKBP5 Show Interactive Effects in Predicting Remission to Antidepressant Treatment
[PMID 19758789] HTR2A gene variation is involved in antidepressant treatment response
[PMID 22006095] Serotonin receptor 2A (HTR2A) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorder
[PMID 18803430] Pharmacogenetics of major depression: insights from level 1 of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial.
[PMID 19077664] Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response.
[PMID 19381154] Differences and similarities in the serotonergic diathesis for suicide attempts and mood disorders: a 22-year longitudinal gene-environment study.
[PMID 19937159] HTR2A is associated with SSRI response in major depressive disorder in a Japanese cohort.
[PMID 20047709] Genetic variation in HTR2A influences serotonin transporter binding potential as measured using PET and [11C]DASB.
[PMID 20194481] Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder.
[PMID 20453658] 5HT1A and 5HT2A receptor genes in treatment response phenotypes in major depressive disorder.
[PMID 21136126] Temperament profiles, 5-HT2A genotype, and response to treatment with SSRIs in major depression.
[PMID 21172166] Pharmacogenetics of antidepressant response.
[PMID 21741447] Interaction between two HTR2A polymorphisms and gender is associated with treatment response in MDD.
| GET Evidence | |
|---|---|
| rs7997012 | |
| aa_change | |
| aa_change_short | |
| impact | pharmacogenetic |
| qualified_impact | Insufficiently evaluated pharmacogenetic |
| overall_frequency | 0.765625 |
| summary | |
